Cite
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
MLA
Schiff, David, et al. “Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.” Cancer, vol. 124, no. 7, Apr. 2018, pp. 1455–63. EBSCOhost, https://doi.org/10.1002/cncr.31219.
APA
Schiff, D., Jaeckle, K. A., Anderson, S. K., Galanis, E., Giannini, C., Buckner, J. C., Stella, P., Flynn, P. J., Erickson, B. J., Schwerkoske, J. F., Kaluza, V., Twohy, E., Dancey, J., Wright, J., & Sarkaria, J. N. (2018). Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer, 124(7), 1455–1463. https://doi.org/10.1002/cncr.31219
Chicago
Schiff, David, Kurt A Jaeckle, S Keith Anderson, Evanthia Galanis, Caterina Giannini, Jan C Buckner, Phillip Stella, et al. 2018. “Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.” Cancer 124 (7): 1455–63. doi:10.1002/cncr.31219.